Recursion Pharmaceuticals Inc.
6 clinical trials · Sponsor
◉ Watch Recursion Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer (NCT06678659) | Recursion Pharmaceuticals Inc. | 2024-11-21 |
| The Clostridioides Difficile Trial of REC-3964 (NCT06536465) | Recursion Pharmaceuticals Inc. | 2024-10-14 |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation (NCT06005974) | Recursion Pharmaceuticals Inc. | 2024-01-15 |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) (NCT05552755) | Recursion Pharmaceuticals Inc. | 2023-07-10 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (NCT05130866) | Recursion Pharmaceuticals Inc. | 2022-06-20 |
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 (NCT05085561) | Recursion Pharmaceuticals Inc. | 2022-03-17 |
Track Recursion Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.